Matthew Deen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matthew Deen has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- David J. Vocadlo
Department of Chemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada
4 shared publications - Pierre-André Gilormini
Department of Chemistry Simon Fraser University Burnaby British Columbia V5A 1S6 Canada
3 shared publications Xi Chen
Department of Chemistry, Simon Fraser University
3 shared publications- Anastasia G. Henry
Denali Therapeutics, South San Francisco, CA 94080, USA
2 shared publications - Marcus Y. Chin
Denali Therapeutics Inc., South San Francisco, CA 94080 USA
2 shared publications - Oliver B. Davis
Denali Therapeutics
2 shared publications
Latest Publications
- Open Access
A lysyl oxidase (LOX)/bone morphogenetic protein-1 (BMP1) complex to facilitate collagen remodeling
Collagen biosynthesis within the extracellular matrix (ECM) relies on finely regulated enzymatic steps to ensure proper collagen maturation and fibrillar assembly. Among these, bone morphogenetic protein-1 (BMP1) and the canonical lysyl oxidase (LOX) act on the collagen telopeptide to promote procollagen processing and oxidative cross-linking, respectively. However, the mechanisms that ensure precise coordination of their activities remain poorly understood. Using NanoBiT assays, we identified and characterized a stable LOX/BMP1 protein complex that assembles intracellularly during trafficking through the ER/Golgi pathway and persists after secretion. Analysis of BMP1 and LOX domains involved in the interaction showed that BMP1 binding requires its CUB2/3 domains, while LOX recognition depends on a conserved, positively charged segment of LOX (residues 259–285) located immediately upstream of its catalytic domain. Formation of the LOX/BMP1 complex did not substantially alter LOX enzymatic activity but markedly enhanced LOX association with collagen type I through the carboxy-telopeptide region, facilitating the assembly of a ternary LOX/BMP1/collagen complex. This pre-assembled complex promoted efficient targeting of LOX to nascent collagen fibrils. Our findings reveal a previously unrecognized layer of regulation in collagen biosynthesis, in which LOX and BMP1 act as a functional unit to ensure precise localization and proper processing of collagen. This mechanism offers new insights into ECM assembly and identifies the LOX/BMP1 interface as a potentially druggable node for anti-fibrotic strategies.
Open AccessA lysyl oxidase (LOX)/bone morphogenetic protein-1 (BMP1) complex to facilitate collagen remodeling
Collagen biosynthesis within the extracellular matrix (ECM) relies on finely regulated enzymatic steps to ensure proper collagen maturation and fibrillar assembly. Among these, bone morphogenetic protein-1 (BMP1) and the canonical lysyl oxidase (LOX) act on the collagen telopeptide to promote procollagen processing and oxidative cross-linking, respectively. However, the mechanisms that ensure precise coordination of their activities remain poorly understood. Using NanoBiT assays, we identified and characterized a stable LOX/BMP1 protein complex that assembles intracellularly during trafficking through the ER/Golgi pathway and persists after secretion. Analysis of BMP1 and LOX domains involved in the interaction showed that BMP1 binding requires its CUB2/3 domains, while LOX recognition depends on a conserved, positively charged segment of LOX (residues 259–285) located immediately upstream of its catalytic domain. Formation of the LOX/BMP1 complex did not substantially alter LOX enzymatic activity but markedly enhanced LOX association with collagen type I through the carboxy-telopeptide region, facilitating the assembly of a ternary LOX/BMP1/collagen complex. This pre-assembled complex promoted efficient targeting of LOX to nascent collagen fibrils. Our findings reveal a previously unrecognized layer of regulation in collagen biosynthesis, in which LOX and BMP1 act as a functional unit to ensure precise localization and proper processing of collagen. This mechanism offers new insights into ECM assembly and identifies the LOX/BMP1 interface as a potentially druggable node for anti-fibrotic strategies.
- Open Access
- 10 February 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (2) , 217-232
Pharmacological inhibition of O-GlcNAcase reduces pS129-α-synuclein positive aggregates in the substantia nigra of mThy1-hSNCA mice
Background: The aggregation and spread of α-synuclein within brain are associated with the loss of dopaminergic neurons and the formation of Lewy bodies as seen in Parkinson's disease. Blocking the initiation of α-synuclein aggregation, or the spread of such aggregates, may offer disease-modifying approaches to slow disease progression. Previous studies have demonstrated that modification of aggregation prone proteins, including α-synuclein, with O-linked β- N -acetylglucosamine (O-GlcNAc) reduces their aggregation. Small molecule inhibitors of the enzyme O-GlcNAcase (OGA), which removes O-GlcNAc from proteins, confers neuroprotective benefits in various preclinical disease models of Alzheimer's and Parkinson's diseases. Objective: This study investigates the effects of long-term pharmacological enhancement of O-GlcNAcylation in a transgenic mouse model of Parkinson's disease overexpressing human α-synuclein. Methods: Thiamet-G was orally administered to mThy1-hSNCA and wild-type (WT) mice for ten months. Behavioral assessments were conducted to examine changes in locomotion and cognition. Histological analyses were performed to analyze α-synuclein aggregates and dopaminergic neurons in brain sections. Immunoblot and ELISA analyses were performed to analyze O-GlcNAc and soluble α-synuclein using brain lysates, respectively. Results: Thiamet-G increased the level of O-GlcNAc in the brain of both mThy1-hSNCA and WT mice. The levels of total α-synuclein in the brain were unaltered. However, Thiamet-G strongly attenuated the deposition of pS129-immunoreactive α-synuclein aggregates within the substantia nigra, prior to observable neurodegeneration. Thiamet-G also protected against locomotor decline. Conclusions: These results support OGA inhibition as a therapeutic approach to block the pathological formation of toxic α-synuclein as a disease-modifying treatment against Parkinson's disease.
- 10 February 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (2) , 217-232
Open AccessPharmacological inhibition of O-GlcNAcase reduces pS129-α-synuclein positive aggregates in the substantia nigra of mThy1-hSNCA mice
Background: The aggregation and spread of α-synuclein within brain are associated with the loss of dopaminergic neurons and the formation of Lewy bodies as seen in Parkinson's disease. Blocking the initiation of α-synuclein aggregation, or the spread of such aggregates, may offer disease-modifying approaches to slow disease progression. Previous studies have demonstrated that modification of aggregation prone proteins, including α-synuclein, with O-linked β- N -acetylglucosamine (O-GlcNAc) reduces their aggregation. Small molecule inhibitors of the enzyme O-GlcNAcase (OGA), which removes O-GlcNAc from proteins, confers neuroprotective benefits in various preclinical disease models of Alzheimer's and Parkinson's diseases. Objective: This study investigates the effects of long-term pharmacological enhancement of O-GlcNAcylation in a transgenic mouse model of Parkinson's disease overexpressing human α-synuclein. Methods: Thiamet-G was orally administered to mThy1-hSNCA and wild-type (WT) mice for ten months. Behavioral assessments were conducted to examine changes in locomotion and cognition. Histological analyses were performed to analyze α-synuclein aggregates and dopaminergic neurons in brain sections. Immunoblot and ELISA analyses were performed to analyze O-GlcNAc and soluble α-synuclein using brain lysates, respectively. Results: Thiamet-G increased the level of O-GlcNAc in the brain of both mThy1-hSNCA and WT mice. The levels of total α-synuclein in the brain were unaltered. However, Thiamet-G strongly attenuated the deposition of pS129-immunoreactive α-synuclein aggregates within the substantia nigra, prior to observable neurodegeneration. Thiamet-G also protected against locomotor decline. Conclusions: These results support OGA inhibition as a therapeutic approach to block the pathological formation of toxic α-synuclein as a disease-modifying treatment against Parkinson's disease.
- Open Access
Direct and indirect regulation of β-glucocerebrosidase by the transcription factors USF2 and ONECUT2
Mutations in the GBA gene, which encodes the lysosomal enzyme β-glucocerebrosidase (GCase), are the most prevalent genetic susceptibility factor for Parkinson’s disease (PD). However, only approximately 20% of carriers develop the disease, suggesting the presence of genetic modifiers influencing the risk of developing PD in the presence of GBA mutations. Here we screened 1,634 human transcription factors (TFs) for their effect on GCase activity in cell lysates of the human glioblastoma line LN-229, into which we introduced the pathogenic GBA L444P variant via adenine base editing. Using a novel arrayed CRISPR activation library, we uncovered 11 TFs as regulators of GCase activity. Among these, activation of MITF and TFEC increased lysosomal GCase activity in live cells, while activation of ONECUT2 and USF2 decreased it. Conversely, ablating USF2 increased GBA mRNA and led to enhanced levels of GCase protein and activity. While MITF, TFEC, and USF2 affected GBA transcription, ONECUT2 was found to control GCase trafficking by modulating the guanine exchange factors PLEKHG4 and PLEKHG4B. Hence, our study provides a systematic approach to identifying modulators of GCase activity, expands the transcriptional landscape of GBA regulation, and deepens our understanding of the mechanisms involved in influencing GCase activity.
Open AccessDirect and indirect regulation of β-glucocerebrosidase by the transcription factors USF2 and ONECUT2
Mutations in the GBA gene, which encodes the lysosomal enzyme β-glucocerebrosidase (GCase), are the most prevalent genetic susceptibility factor for Parkinson’s disease (PD). However, only approximately 20% of carriers develop the disease, suggesting the presence of genetic modifiers influencing the risk of developing PD in the presence of GBA mutations. Here we screened 1,634 human transcription factors (TFs) for their effect on GCase activity in cell lysates of the human glioblastoma line LN-229, into which we introduced the pathogenic GBA L444P variant via adenine base editing. Using a novel arrayed CRISPR activation library, we uncovered 11 TFs as regulators of GCase activity. Among these, activation of MITF and TFEC increased lysosomal GCase activity in live cells, while activation of ONECUT2 and USF2 decreased it. Conversely, ablating USF2 increased GBA mRNA and led to enhanced levels of GCase protein and activity. While MITF, TFEC, and USF2 affected GBA transcription, ONECUT2 was found to control GCase trafficking by modulating the guanine exchange factors PLEKHG4 and PLEKHG4B. Hence, our study provides a systematic approach to identifying modulators of GCase activity, expands the transcriptional landscape of GBA regulation, and deepens our understanding of the mechanisms involved in influencing GCase activity.
- 28 August 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (40)
A Fixable Fluorescence‐Quenched Substrate for Quantitation of Lysosomal Glucocerebrosidase Activity in Both Live and Fixed Cells
Fluorogenic substrates are emerging tools that enable studying enzymatic processes within their native cellular environments. However, fluorogenic substrates that function within live cells are generally incompatible with cellular fixation, preventing their tandem application with fundamental cell biology methods such as immunocytochemistry. Here we report a simple approach to enable the chemical fixation of a dark‐to‐light substrate, LysoFix‐GBA, which enables quantification of glucocerebrosidase (GCase) activity in both live and fixed cells. LysoFix‐GBA enables measuring responses to both chemical and genetic perturbations to lysosomal GCase activity. Further, LysoFix‐GBA permits simple multiplexed co‐localization studies of GCase activity with subcellular protein markers. This tool will aid studying the role of GCase activity in Parkinson's Disease, creating new therapeutic approaches targeting the GCase pathway. This approach also lays the foundation for an approach to create fixable substrates for other lysosomal enzymes.
- 28 August 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (40)
A Fixable Fluorescence‐Quenched Substrate for Quantitation of Lysosomal Glucocerebrosidase Activity in Both Live and Fixed Cells
Fluorogenic substrates are emerging tools that enable studying enzymatic processes within their native cellular environments. However, fluorogenic substrates that function within live cells are generally incompatible with cellular fixation, preventing their tandem application with fundamental cell biology methods such as immunocytochemistry. Here we report a simple approach to enable the chemical fixation of a dark‐to‐light substrate, LysoFix‐GBA, which enables quantification of glucocerebrosidase (GCase) activity in both live and fixed cells. LysoFix‐GBA enables measuring responses to both chemical and genetic perturbations to lysosomal GCase activity. Further, LysoFix‐GBA permits simple multiplexed co‐localization studies of GCase activity with subcellular protein markers. This tool will aid studying the role of GCase activity in Parkinson's Disease, creating new therapeutic approaches targeting the GCase pathway. This approach also lays the foundation for an approach to create fixable substrates for other lysosomal enzymes.
- 28 August 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (40) , e202309306
A Fixable Fluorescence‐Quenched Substrate for Quantitation of Lysosomal Glucocerebrosidase Activity in Both Live and Fixed Cells
Fluorogenic substrates are emerging tools that enable studying enzymatic processes within their native cellular environments. However, fluorogenic substrates that function within live cells are generally incompatible with cellular fixation, preventing their tandem application with fundamental cell biology methods such as immunocytochemistry. Here we report a simple approach to enable the chemical fixation of a dark‐to‐light substrate, LysoFix‐GBA, which enables quantification of glucocerebrosidase (GCase) activity in both live and fixed cells. LysoFix‐GBA enables measuring responses to both chemical and genetic perturbations to lysosomal GCase activity. Further, LysoFix‐GBA permits simple multiplexed co‐localization studies of GCase activity with subcellular protein markers. This tool will aid studying the role of GCase activity in Parkinson's Disease, creating new therapeutic approaches targeting the GCase pathway. This approach also lays the foundation for an approach to create fixable substrates for other lysosomal enzymes.
- 28 August 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (40) , e202309306
A Fixable Fluorescence‐Quenched Substrate for Quantitation of Lysosomal Glucocerebrosidase Activity in Both Live and Fixed Cells
Fluorogenic substrates are emerging tools that enable studying enzymatic processes within their native cellular environments. However, fluorogenic substrates that function within live cells are generally incompatible with cellular fixation, preventing their tandem application with fundamental cell biology methods such as immunocytochemistry. Here we report a simple approach to enable the chemical fixation of a dark‐to‐light substrate, LysoFix‐GBA, which enables quantification of glucocerebrosidase (GCase) activity in both live and fixed cells. LysoFix‐GBA enables measuring responses to both chemical and genetic perturbations to lysosomal GCase activity. Further, LysoFix‐GBA permits simple multiplexed co‐localization studies of GCase activity with subcellular protein markers. This tool will aid studying the role of GCase activity in Parkinson's Disease, creating new therapeutic approaches targeting the GCase pathway. This approach also lays the foundation for an approach to create fixable substrates for other lysosomal enzymes.
- 1 February 2016
- Published by Canadian Science Publishing in Canadian Journal of Chemistry
- Vol. 94 (2) , 170-175
Electrodeposition of metal cations from the wet ionic liquid [EMIM][TFSI]
We investigated the deposition of silver, copper, and lead from the ionic liquid 1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide [EMIM][TFSI] under potentiostatic conditions in the presence of water. This was part of a larger project involving the extraction of metal ions from mining waste into an ionic liquid followed by electrodeposition so that the ionic liquid could be recycled. All three elements were deposited in metallic form by electrolysis in the ionic liquid, and the process was enhanced rather than hindered by the presence of water. The deposited metals did not adhere strongly to the cathode of the electrochemical cell, especially when Ebonex® was used as the cathode. The deposition of silver showed little temperature dependence, and at temperatures close to ambient, the ionic liquid was not adversely affected. The deposits of copper and lead gradually re-dissolved after electrodeposition, suggesting that chemical re-oxidation of these metals by air is more facile in the ionic liquid than in water. Copper showed strong evidence of formation of a Cu+ species upon reduction of Cu2+ (not seen in water); lead (Pb2+) showed evidence of a time-dependent complexation with the anions of the ionic liquid.
- 1 February 2016
- Published by Canadian Science Publishing in Canadian Journal of Chemistry
- Vol. 94 (2) , 170-175
Electrodeposition of metal cations from the wet ionic liquid [EMIM][TFSI]
We investigated the deposition of silver, copper, and lead from the ionic liquid 1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide [EMIM][TFSI] under potentiostatic conditions in the presence of water. This was part of a larger project involving the extraction of metal ions from mining waste into an ionic liquid followed by electrodeposition so that the ionic liquid could be recycled. All three elements were deposited in metallic form by electrolysis in the ionic liquid, and the process was enhanced rather than hindered by the presence of water. The deposited metals did not adhere strongly to the cathode of the electrochemical cell, especially when Ebonex® was used as the cathode. The deposition of silver showed little temperature dependence, and at temperatures close to ambient, the ionic liquid was not adversely affected. The deposits of copper and lead gradually re-dissolved after electrodeposition, suggesting that chemical re-oxidation of these metals by air is more facile in the ionic liquid than in water. Copper showed strong evidence of formation of a Cu+ species upon reduction of Cu2+ (not seen in water); lead (Pb2+) showed evidence of a time-dependent complexation with the anions of the ionic liquid.